Active, not recruitingPhase 2NCT04392037
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amsterdam UMC, location VUmc
- Principal Investigator
- N.W.C.J van de Donk, Prof. MD PhDAmsterdam UMC, location VUmc
- Intervention
- Iberdomide plus low-dose cyclophosphamide and dexamethasone(drug)
- Enrollment
- 60 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (9)
- NWZ, Alkmaar, Netherlands
- Amsterdam UMC, location AMC, Amsterdam, Netherlands
- Amsterdam UMC, location VUmc, Amsterdam, Netherlands
- Rijnstate, Arnhem, Netherlands
- Amphia Ziekenhuis, Breda, Netherlands
- Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
- UMC Groningen, Groningen, Netherlands
- Antonius ziekenhuis, Nieuwegein, Netherlands
- Radboud UMC, Nijmegen, Netherlands
Collaborators
Celgene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04392037 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University